The NCI-H358 cell line was first established in 1981 from removed bronchiole tissue of a patient suffering from bronchioalveolar carcinoma (lung cancer). The tissue was removed from the patient prior to any administered chemotherapy treatments. The NCI-H358 cell line has a doubling time of about 38 hours, it has detectable Clara cells and is an exceptional transfection host. This cell line is also a great candidate for in vitro research studies, such as those at Altogen Biosystems . T he in vitro research models are helpful to solving lung cancer and useful as transfection hosts. Transfection Reagent for NCI-H358 Cells (Bronchioalveolar Cells, CRL-5807)